Pharmaceutical company intelligence reports from Espicom provide a full review of the company's activities together with five-year sales forecasts for its key products. The company's financial performance is covered in-depth, from its latest results to a complete analysis of its latest full fiscal year and an outlook for the future. A section on company strategy covers mergers, acquisitions and divestitures, key agreements, products and R&D. An overview of key products and R&D is followed by a comprehensive review of the company's product portfolio and research and development pipeline by therapeutic area. In addition, supplementary appendices provide more in-depth information on financials, agreements and corporate events. Altana AG is an international pharmaceuticals and chemicals group with approximately 13,400 employees worldwide. The Altana Group is composed of the strategic management holding company, Altana AG, and two operating divisions, Altana Pharma AG and ALTANA Chemie AG.

Altana Pharma AG, headquartered in Konstanz, Germany, is an international pharmaceutical group with more than 8,800 employees and over 30 subsidiaries in Europe, North and Latin America, Asia, South Africa and Australia. The company concentrates on innovative pharmaceutical products in therapeutics, imaging (contrast media) and OTC medication. Therapeutics, the most important business area, is based on prescription drugs for gastrointestinal and respiratory diseases.

Current Growth Drivers
Pantozol (pantoprazole) was the third proton pump inhibitor (PPI) to be developed worldwide and has been extensively licensed to companies around the globe. In 2005, pantoprazole generated over half of Altana's pharmaceutical sales.

Key Late-Stage Products
Daxas (roflumilast) is an oral, once-daily, selective phosphodiesterase IV inhibitor, in Phase III trials for the treatment of asthma and COPD. It may also have potential in several other inflammatory conditions, including atopic dermatitis and psoriasis. The company considers Daxas to have blockbuster potential.